Sacituzumab Govitecan in Advanced Triple-Negative Breast Cancer - PubMed
5 hours ago
- #clinical trial
- #immunotherapy
- #breast cancer
- The article comments on the use of Sacituzumab Govitecan in untreated, advanced triple-negative breast cancer.
- A related clinical trial (N Engl J Med. 2025 Nov 13) discusses the drug's efficacy in this patient population.
- The referenced study was published online in October 2025, with specific details available via its PMID and DOI.